Panacea Biotec to produce up to 25 million Sputnik V doses
New Delhi: Panacea Biotec on Thursday said it has entered into a pact to produce up to 25 million doses of Sputnik V COVID-19 vaccine using the drug substance manufactured by pharma firm Generium in Russia.The company has entered into a "licensing and manufacturing agreement with Human Vaccine Limited Liability Company, a subsidiary of Russian Direct Investment Fund, Russia, Generium Joint...
New Delhi: Panacea Biotec on Thursday said it has entered into a pact to produce up to 25 million doses of Sputnik V COVID-19 vaccine using the drug substance manufactured by pharma firm Generium in Russia.
The company has entered into a "licensing and manufacturing agreement with Human Vaccine Limited Liability Company, a subsidiary of Russian Direct Investment Fund, Russia, Generium Joint Stock Company, Russia, and Dr Reddy's Laboratories Ltd," Panacea Biotec said in a filing to BSE.
As per the terms of this agreement, Panacea Biotec shall produce the Sputnik V vaccine using the ready-to-fill drug substance manufactured by Generium in Russia, and then supply the entire quantity to Dr Reddy's for distribution in India, it added.
Read also: Release over Rs 14 crore to Panacea Biotec for manufacturing Sputnik V: Delhi HC tells Center
"The agreement is for manufacture (fill and finish) of upto 25 million doses of Sputnik V vaccine," Panacea Biotec added.
Read also: Panacea Biotec gets DCGI license to manufacture Sputnik V
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd